CTX310 (Bayer collab.)
Cardiovascular Disease (e.g., ATTR amyloidosis)
PreclinicalResearch
Key Facts
Indication
Cardiovascular Disease (e.g., ATTR amyloidosis)
Phase
Preclinical
Status
Research
Company
About CRISPR Therapeutics
CRISPR Therapeutics is a pioneering biopharmaceutical company dedicated to discovering, developing, and commercializing curative gene-editing treatments. Founded by CRISPR gene-editing pioneers, the company leverages its proprietary CRISPR/Cas9 platform to create a diverse pipeline targeting hemoglobinopathies, immuno-oncology, regenerative medicine, and in vivo diseases. Its landmark achievement is the approval of CASGEVY, the world's first CRISPR/Cas9 gene-edited therapy, marking a new era in medicine and validating its platform's potential. The company collaborates with Vertex Pharmaceuticals and Bayer to accelerate development and commercialization across multiple therapeutic areas.
View full company profile